Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.15 USD | +2.18% | +1.98% | +5.32% |
Financials (USD)
Sales 2024 * | 21.4M | Sales 2025 * | 89.52M | Capitalization | 159M |
---|---|---|---|---|---|
Net income 2024 * | -33M | Net income 2025 * | 8M | EV / Sales 2024 * | 7.42 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.77 x |
P/E ratio 2024 * |
-5.22
x | P/E ratio 2025 * |
51.7
x | Employees | 102 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.8% |
Latest transcript on Capricor Therapeutics, Inc.
1 day | +2.18% | ||
1 week | +1.98% | ||
Current month | -24.15% | ||
1 month | -22.32% | ||
3 months | +25.61% | ||
6 months | +84.59% | ||
Current year | +5.32% |
Managers | Title | Age | Since |
---|---|---|---|
Linda Marbán
CEO | Chief Executive Officer | 60 | 13-11-19 |
Anthony Bergmann
DFI | Director of Finance/CFO | 38 | 13-11-19 |
Kristi Elliott
CTO | Chief Tech/Sci/R&D Officer | - | 20-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Philip Gotwals
BRD | Director/Board Member | 61 | 23-07-20 |
Earl Collier
BRD | Director/Board Member | 76 | 13-11-19 |
George Dunbar
BRD | Director/Board Member | 77 | 13-11-19 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 5.15 | +2.18% | 387,923 |
24-04-24 | 5.04 | +4.56% | 919,728 |
24-04-23 | 4.82 | -2.43% | 478,470 |
24-04-22 | 4.94 | -1.40% | 357,005 |
24-04-19 | 5.01 | -0.79% | 354,057 |
Delayed Quote Nasdaq, April 25, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.32% | 159M | |
-2.26% | 104B | |
+1.41% | 97.42B | |
+0.79% | 22.2B | |
-17.84% | 21.23B | |
-11.11% | 18.33B | |
-42.83% | 16.35B | |
-17.63% | 15.06B | |
+4.55% | 13.98B | |
+32.11% | 11.66B |
- Stock Market
- Equities
- CAPR Stock